Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRX-1074 in Major Depressive Disorder
NCT02067793Phase 2Completed
- Sponsor
- Allergan
- Start
- Mar 2014
- Primary completion
- Feb 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apimostinel in major depressive disorder (MDD), sponsored by Allergan. Started Mar 2014; status: completed.
02
Drugs
apimostinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02067793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02067793.